Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factors in Inflammatory Bowel Disease

Saved in:
Bibliographic Details
Published inThe American journal of gastroenterology Vol. 120; no. 1; p. 259
Main Authors Dai, Cong, Huang, Yu-hong, Jiang, Min
Format Journal Article
LanguageEnglish
Published Philadelphia, PA Wolters Kluwer 01.01.2025
Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
Subjects
Infections
Inflammatory bowel disease
TNF inhibitors
Tumor necrosis factor-TNF
Online AccessGet full text
ISSN0002-9270
1572-0241
1572-0241
DOI10.14309/ajg.0000000000002995

Cover

More Information
Bibliography:Correspondence: Cong Dai, MD, PhD. E-mail: congdai2006@sohu.com.
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:0002-9270
1572-0241
1572-0241
DOI:10.14309/ajg.0000000000002995